Rx Mobile Devices Promos: Benefits Often More Prominent Than Risks
In an analysis of direct-to-consumer mobile promotions, FDA found that risks and benefits are not equally prominent and accessible in the communications and their landing pages.
You may also be interested in...
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
Referencing opioids and suicidal thoughts is not sufficient, US regulators say; letter comes as Orexigen has seen an upsurge in Contrave prescriptions.
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.